A- A A+

Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis. 

Garg R, Kitchen SA, Men S, Campbell TJ, Bozinoff N, Tadrous M, Antoniou T, Wyman J, Werb D, Munro C, Gomes T. 

Drug Alcohol Depend. 2022 Jul 1;236:109459. doi: 10.1016/j.drugalcdep.2022.109459. Epub 2022 Apr 14. PMID: 35489179; PMCID: PMC9008980.


A qualitative study exploring the impact of the COVID-19 pandemic on People Who Inject Drugs (PWID) and drug service provision in the UK: PWID and service provider perspectives. 

May T, Dawes J, Fancourt D, Burton A. 

Int J Drug Policy. 2022 May 27;106:103752. doi: 10.1016/j.drugpo.2022.103752. Epub ahead of print. PMID: 35653821; PMCID: PMC9135844.


Impact of reduced restrictions on buprenorphine prescribing during COVID-19 among patients in a community-based treatment program. 

Ward KM, Scheim A, Wang J, Cocchiaro B, Singley K, Roth AM. 

Drug Alcohol Depend Rep. 2022 Jun;3:100055. doi: 10.1016/j.dadr.2022.100055. Epub 2022 Apr 26. PMID: 35497489; PMCID: PMC9040407.


Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis. 

Hoffman KA, Foot C, Levander XA, Cook R, Terashima JP, McIlveen JW, Korthuis PT, McCarty D. 

J Subst Abuse Treat. 2022 May 8:108801. doi: 10.1016/j.jsat.2022.108801. Epub ahead of print. PMID: 35589443; PMCID: PMC9080674.


A qualitative study exploring the impact of the COVID-19 pandemic on People Who Inject Drugs (PWID) and drug service provision in the UK: PWID and service provider perspectives. 

May T, Dawes J, Fancourt D, Burton A. 

Int J Drug Policy. 2022 May 27;106:103752. doi: 10.1016/j.drugpo.2022.103752. Epub ahead of print. PMID: 35653821; PMCID: PMC9135844.


Treatment of Opioid Use Disorder With Buprenorphine Among US Adolescents and Young Adults During the Early COVID-19 Pandemic.

Alinsky RH, Prichett L, Chang HY, Alexander GC, Stein BD, Saloner B. 

J Adolesc Health. 2022 May 8:S1054-139X(22)00383-4. doi: 10.1016/j.jadohealth.2022.03.015. Epub ahead of print. PMID: 35595609; PMCID: PMC9110275.


Changes in transmucosal buprenorphine utilization for opioid use disorder treatment during the COVID-19 pandemic in Kentucky. 

Lei F, Lofwall MR, Freeman PR, Slade E, Vickers-Smith R, Slavova S. 

J Rural Health. 2022 May 24. doi: 10.1111/jrh.12669. Epub ahead of print. PMID: 35610181.


Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic. 

Nguyen T, Ziedan E, Simon K, Miles J, Crystal S, Samples H, Gupta S. 

JAMA Netw Open. 2022 Jun 1;5(6):e2214765. doi: 10.1001/jamanetworkopen.2022.14765. PMID: 35648400.


Prevention, treatment and care of substance use disorders in times of COVID-19. 

Volkow ND, Maua S, Campello G, Poznyak V, Krupchanka D, Kashino W, Busse A. 

World Psychiatry. 2022 Jun;21(2):323-324. doi: 10.1002/wps.20995. PMID: 35524627; PMCID: PMC9077610.


Factors associated with 60-day adherence to "safer supply" opioids prescribed under British Columbia's interim clinical guidance for health care providers to support people who use drugs during COVID-19 and the ongoing overdose emergency. 

Selfridge M, Card K, Kandler T, Flanagan E, Lerhe E, Heaslip A, Nguyen A, Moher M, Pauly B, Urbanoski K, Fraser C. 

Int J Drug Policy. 2022 May 3;105:103709. doi: 10.1016/j.drugpo.2022.103709. Epub ahead of print. PMID: 35525052; PMCID: PMC9065674.


USA. On-demand buprenorphine clinic reaches every corner of Oregon

In fall 2019, Oregon Health & Science University opened a clinic to provide same-day, walk-in access to proven medications to treat opioid use disorder. 

Within a few months, the COVID-19 pandemic forced the clinic to switch to virtual care.

Now, with the pandemic receding, the clinic intends to stick with its virtual care model to provide buprenorphine for patients with opioid addiction. The reason: The remote model enables the clinic to extend services to patients in every corner of Oregon. In addition, a newly published study in the journal Substance Abuse suggests that many patients prefer it. (MedicalXpress, USA, 16.05.2022)


Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements. 

Spetz J, Hailer L, Gay C, Tierney M, Schmidt L, Phoenix B, Chapman S. 

JAMA Netw Open. 2022 May 2;5(5):e225996. doi: 10.1001/jamanetworkopen.2022.5996. PMID: 35552728.


Digital Health Interventions for Delivery of Mental Health Care: Systematic and Comprehensive Meta-Review. 

Philippe TJ, Sikder N, Jackson A, Koblanski ME, Liow E, Pilarinos A, Vasarhelyi K. 

JMIR Ment Health. 2022 May 12;9(5):e35159. doi: 10.2196/35159. PMID: 35551058; PMCID: PMC9109782.


A multicentric survey among patients with substance use disorders during the COVID-19 lockdown in India. 

Arya S, Ghosh A, Mishra S, Swami MK, Prasad S, Somani A, Basu A, Sharma K, Padhy SK, Nebhinani N, Singh LK, Choudhury S, Basu D, Gupta R. 

Indian J Psychiatry. 2022 Jan-Feb;64(1):48-55. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_557_21. Epub 2022 Jan 21. PMID: 35400749; PMCID: PMC8992763.


Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions. 

Bouck Z, Scheim AI, Gomes T, Ling V, Caudarella A, Werb D. 

Int J Drug Policy. 2022 Apr 13;104:103680. doi: 10.1016/j.drugpo.2022.103680. Epub ahead of print. PMID: 35447476; PMCID: PMC9005368.


HIV Care Continuum Services for People Who Inject Drugs in Kazakhstan During COVID-19: A Qualitative Study of Service Provider Perspectives. 

McCrimmon T, Sundelson A, Darisheva M, Gilbert L, Hunt T, Terlikbayeva A, Primbetova S, El-Bassel N. 

Glob Health Sci Pract. 2022 Apr 29;10(2):e2100619. doi: 10.9745/GHSP-D-21-00619. PMID: 35487549; PMCID: PMC9053153.


Lessons from the First Wave of COVID-19 for Improved Medications for Opioid Use Disorder (MOUD) Treatment: Benefits of Easier Access, Extended Take Homes, and New Delivery Modalities. 

Walters SM, Perlman DC, Guarino H, Mateu-Gelabert P, Frank D. 

Subst Use Misuse. 2022;57(7):1144-1153. doi: 10.1080/10826084.2022.2064509. Epub 2022 Apr 21. PMID: 35443862.



Factors associated with perceived decline in the quality of drugs during the COVID-19 pandemic: Evidence from community-recruited cohorts of people who use drugs in Vancouver, Canada. 

McAdam E, Hayashi K, Dong H, Cui Z, Sedgemore KO, Dietze P, Phillips P, Wilson D, Milloy MJ, DeBeck K. 

Drug Alcohol Depend. 2022 Apr 25;236:109471. doi: 10.1016/j.drugalcdep.2022.109471. Epub ahead of print. PMID: 35489180; PMCID: PMC9043624.


Kanada. Research probes effect of pandemic on treatment of people who use fentanyl

How has the pandemic affected people who use the potentially deadly street drug fentanyl and those who treat them?

A research project by University of Windsor social work professor Adrian Guta will delve into this question, shedding light on the wider impact the pandemic has had on Canadian society.

“In the context of the pandemic, there’s been a lot of change in how we’re responding to opioid addiction and the drug crisis,” Dr. Guta said. “We know the pandemic has complicated access to care and treatment.” (University of Windsor, Kanda, 02.05.2022)


What factors influence retention in buprenorphine and methadone treatment?

Medication treatments for opioid use disorder are effective lifesaving therapies, and studies suggest that longer treatment durations result in better patient outcomes (e.g., reduced overdose death risk, less use of ambulatory care services). Identifying the factors that best predict retention can ultimately help us develop and roll out strategies to enhance retention. In this study, the researchers examined which factors were the strongest predictors of medication retention in an Australian sample. (Recovery Research Institute, USA, 22.04.2022)


A novel home- and community-based mobile outreach detoxification service for individuals identifying problematic substance use: implementation and program evaluation. 

Lodge A, Partyka C, Surbey K. 

Can J Public Health. 2022 Apr 20:1–7. doi: 10.17269/s41997-022-00640-w. Epub ahead of print. PMID: 35442006; PMCID: PMC9020145.


The impact of the COVID-19 pandemic on illicit drug supply, drug-related behaviour of people who use drugs and provision of drug related services in Georgia: results of a mixed methods prospective cohort study. 

Otiashvili D, Mgebrishvili T, Beselia A, Vardanashvili I, Dumchev K, Kiriazova T, Kirtadze I. 

Harm Reduct J. 2022 Mar 9;19(1):25. doi: 10.1186/s12954-022-00601-z. PMID: 35264181; PMCID: PMC8906357.


Opioid treatment program safety measures during the COVID-19 pandemic: a statewide survey. 

Bandara S, Maniates H, Hulsey E, Smith JS, DiDomenico E, Stuart EA, Saloner B, Krawczyk N. 

BMC Health Serv Res. 2022 Mar 30;22(1):418. doi: 10.1186/s12913-022-07832-7. PMID: 35354460; PMCID: PMC8965537.


Structural Adaptations to Methadone Maintenance Treatment and Take-Home Dosing for Opioid Use Disorder in the Era of COVID-19. 

Suen LW, Coe WH, Wyatt JP, Adams ZM, Gandhi M, Batchelor HM, Castellanos S, Joshi N, Satterwhite S, Pérez-Rodríguez R, Rodríguez-Guerra E, Albizu-Garcia CE, Knight KR, Jordan A. 

Am J Public Health. 2022 Apr;112(S2):S112-S116. doi: 10.2105/AJPH.2021.306654. PMID: 35349324; PMCID: PMC8965183.


Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic. 

Mattocks KM, Moore DT, Wischik DL, Lazar CM, Rosen MI. 

J Subst Abuse Treat. 2022 Mar 25:108777. doi: 10.1016/j.jsat.2022.108777. Epub ahead of print. PMID: 35346533; PMCID: PMC8949846.


Changes in Buprenorphine Prescribing to Medicaid Beneficiaries During the First Year of the COVID-19 Pandemic. 

Dowd WN, Mark TL. 

JAMA Netw Open. 2022 Mar 1;5(3):e224058. doi: 10.1001/jamanetworkopen.2022.4058. PMID: 35323952.


Exploring the impact of COVID-19 on substance use patterns and service access of street involved individuals in Kingston, Ontario: a qualitative study. 

McCann V, Allen R, Purkey E. 

BMC Public Health. 2022 Mar 23;22(1):571. doi: 10.1186/s12889-022-12976-6. PMID: 35317773; PMCID: PMC8940590.


Schweiz. Zusammenwirken in der Krise – Arbeit der Taskforce Sucht und Covid-19

Der Suchtbereich musste sich aufgrund der Corona-Pandemie und den damit einhergehenden Schutzmassnahmen vielfältigen Herausforderungen stellen: Diese reichen von den Einschränkungen des Zugangs zur Suchthilfe und den Befürchtungen negativer Auswirkungen auf den Konsum von psychoaktiven Substanzen bis hin zu schwierig umsetzbaren Schutzmassnahmen in Institutionen aufgrund der Räumlichkeiten. Die Taskforce Sucht und Covid-19 übernimmt in Zusammenarbeit mit den Akteur:innen und Institutionen der Suchthilfe bis heute eine nationale koordinative Rolle in der Bewältigung der Lage. (SuchtMagazin, Schweiz, 1/2022, Schwerpunkt: Corona-Pandemie)


The impact of COVID-19 on access to harm reduction, substance use treatment and recovery services in Scotland: a qualitative study.

Schofield J, Dumbrell J, Matheson C, Parkes T, Bancroft A. 

BMC Public Health. 2022 Mar 15;22(1):500. doi: 10.1186/s12889-022-12873-y. PMID: 35287630; PMCID: PMC8920805.


Navigating intersecting public health crises: a qualitative study of people with opioid use disorders' experiences during the COVID-19 pandemic. 

Watson DP, Staton MD, Grella CE, Scott CK, Dennis ML. 

Subst Abuse Treat Prev Policy. 2022 Mar 18;17(1):22. doi: 10.1186/s13011-022-00449-3. PMID: 35303913; PMCID: PMC8931576.